Through AI platform technologies, we redefine the drug discovery process. Using our deep understanding of the human immune system and our proprietary AI technology, we are able to mimic the human immune system in silico and predict whether the body will have an immune response to certain stimuli.

Based on our state-of-the-art AI platforms PIONEERTM, EDENTM, and RAVENTM, we are advancing a robust product pipeline in immuno-oncology and infectious diseases with primary focus on discovery and early development, building on a simple and scalable business model. We are continuously exploring new frontiers in AI-immunology, including evaluating new therapeutic areas where our know-how and technologies can make a difference such as autoimmune diseases, allergies, microbiome dysbiosis and parasites.